Articles on expensive Coronavirus drug look suspicious

[RandomPoster]

Headline of article praising expensive new Coronavirus drug Remesdivir:

"Early Data from Gilead’s Compassionate Use of Remdesivir for COVID-19 Looks Promising"

"The study of the 53 patients in the U.S., Europe and Canada who required respiratory support showed that about two-thirds benefited from the drug."

If that was Hydroxychloroquine, which sells for about 50 cents a pill, the press would be screaming ANECDOTAL!

Last paragraph:

"That being said, about 25% of patients receiving it have severe side effects, including multiple-organ dysfunction syndrome, septic shock, acute kidney injury and low blood pressure. Another 23% demonstrated evidence of liver damage on lab tests."

Link:

Early Data from Gilead’s Compassionate Use of Remdesivir for COVID-19 Looks Promising | BioSpace

The study of the 53 patients in the U.S., Europe and Canada who required respiratory support showed that about two-thirds benefited from the drug.

www.biospace.com

Quote from another article:

"According to SVB Leerink analyst Geoffrey Porges, remdesivir price is likely to be $5,000 per course in the US, $4,000 per course in Europe, and around $2,000 in other markets. Gilead Sciences (GILD) stock keeps rising."

Gilead (GILD) Stock Rose 1.5% on Remdesivir $7B Sales Prognosis


Then, we later find out the following:

"Lancet backs off study trashing hydroxychloroquine and issues ‘expression of concern’ after the journal was caught using falsified data"

Lancet backs off study trashing hydroxychloroquine and issues 'expression of concern' after the journal was caught using falsified data | Tech News | Startups News